semaglutide fda shortage status january 2025 declares end to Wegovy and Ozempic GLP-1 No Longer on FDA's – FDA reports adverse effects of

is supported by the DFG (SFB974, GRK1949) and the Jrgen Manchot Foundation (MOI)

Diabetologia 53: 153-159, 2010

In her office, parents are often leading the conversation about their teens taking GLP-1s

Skipped doses lead to inconsistent blood levels

For treatment professionals and treatment systems: This study suggests that GLP-1 medications may modestly lower risk for developing substance use disorder and risk of addiction-related problems for those who already have a substance use disorder

Common dosing mistakes and how to avoid them After reviewing thousands of community-reported protocols, certain errors appear repeatedly